Etana Biotech: Pioneering Local Vaccine Production for Indonesia’s Health Independence

Etana Biotechnologies Indonesia (Etana) is at the forefront of Indonesia’s journey to achieve health independence by focusing on local vaccine production. With a commitment to supporting the government’s health initiatives, Etana is determined to provide affordable, high-quality vaccines for the Indonesian population while reducing reliance on imported products.

In 2024, Etana reached a significant milestone by obtaining Good Manufacturing Practice (CPOB) certification and a Distribution Permit Number (NIE) for its locally produced PCV-13 vaccine. This vaccine is now part of the national immunization program, offering a safe and cost-effective solution for preventing pneumococcal infections.

According to Indra Lamora, Director of Anti-Infectious Business Unit at Etana, the availability of PCV-13 will have a profound impact. “As a national biotechnology company, Etana is proud to be trusted by the government to supply PCV-13 for routine immunization programs. This trust motivates us to continue innovating and developing more biotechnology and vaccine products to benefit society,” he stated.

Etana is not only addressing local vaccine needs but also aiming for a global footprint. With its production facilities, the company is targeting exports to ASEAN countries and member states of the Organization of Islamic Cooperation (OIC). This expansion not only enhances Indonesia’s reputation in the global biotechnology industry but also creates employment opportunities and drives economic growth.

In 2025, Etana has outlined two key priorities. First, ensuring the continuous availability of PCV-13 to meet domestic demand and support the government’s immunization programs. Second, advancing the development of innovative vaccines, including those for HPV and tuberculosis. These vaccines are part of the government’s efforts to expand immunization coverage and address pressing public health issues such as cervical cancer and TB transmission.

Etana’s ambitions go beyond these achievements. The company is actively collaborating with leading institutions to tackle other health challenges. For instance, Etana is working with the University of Indonesia (UI), the National Research and Innovation Agency (BRIN), and the Indonesia Endowment Fund for Education (LPDP) to develop a locally produced dengue vaccine.

“Dengue fever remains a serious public health issue in Indonesia. Addressing this requires sustained efforts involving ministries, agencies, industries, and universities,” Indra explained. This initiative underscores Etana’s role as a catalyst for transformative health solutions in Indonesia.

Etana’s efforts align with the government’s vision to enhance health security and improve public well-being. By producing high-quality vaccines locally, Etana not only reduces the country’s dependency on imports but also contributes to economic growth.

“With our commitment to support national health goals, we believe collaboration is the key to building a stronger healthcare system,” Indra concluded.

As Indonesia moves towards health independence, Etana remains a key player, driving innovation and providing sustainable solutions for the nation’s healthcare challenges.